Highlight
– Baricitinib achieved significant hair regrowth (scalp, eyebrows, and eyelashes) in adolescents with severe alopecia areata (AA) after one year27s treatment.
– In patients aged 12 to less than 18 years, 54.1% receiving 4 mg daily attained 80% scalp hair coverage, with up to 80% response in those with recent-onset disease.
– Safety profile in adolescents was consistent with prior adult studies, with no new safety signals over 12 months.
– Eli Lilly plans to file regulatory submissions globally for label expansion and will initiate enrollment of younger children (6 to <12 years) in upcoming trials.
